Portfolio

Kinoxis Therapeutics

First-in-class neuroscience medicines for agitation in dementia.
Up Arrow Icon

Kinoxis Therapeutics

→

Leaders
Hugh Alsop
Hugh Alsop
Co-Founder and CEO
Michael Bowen
Michael Bowen
Co-Founder and CSO
Investment Team
challenges
Agitation and aggression are common to many disorders of the brain and mind and encompass a range of disruptive behaviours such as verbal outbursts, physically harmful actions, restlessness, repetitive behaviours, and excessive negativity. These symptoms can leave patients socially isolated and pose a major challenge for carers
solution
Kinoxis' lead compound is in Phase 1 clinical trials for agitation in dementia, aiming to enter Phase 2 trials in 2027.
For founders

Building for the systems that matter? Pitch us.

We back founders turning breakthrough science into category-defining companies.

Submit your pitch
For investors

Invest with Main Sequence

Access Australia's deep tech frontier alongside us.

Investor enquiries